Mytra (Itraconazole)

Itraconazole is used to manage fungal infections across several disease categories.

• Superficial and systemic mycoses: eradicates the infecting fungus and resolves clinical symptoms.
• Blastomycosis: eliminates Blastomyces dermatitidis organisms and prevents disease progression.
• Histoplasmosis: clears Histoplasma capsulatum infection, especially in disseminated cases.
• Aspergillosis: treats invasive Aspergillus species infections in immunocompromised patients.
• Candidiasis: resolves Candida species infections of mucosal and systemic sites.

• Itraconazole inhibits the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, a key step in ergosterol synthesis. By blocking this enzyme, the drug disrupts the fungal cell membrane structure, leading to increased permeability and ultimately fungal cell death. This mechanism targets a broad spectrum of pathogenic fungi while sparing human cells.

Itraconazole may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools, often self‑limiting.
• Abdominal pain: cramping or discomfort in the stomach area.
• Rash: mild skin irritation or redness.
• Elevated liver enzymes: mild, reversible changes in liver function tests.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury requiring monitoring.
• Congestive heart failure: fluid retention and reduced cardiac function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Visual disturbances: blurred vision or photophobia.
• Anaphylaxis: rare, life‑threatening allergic reaction.
• QT prolongation: potential cardiac rhythm abnormalities.

Before initiating itraconazole therapy, consider the following safety measures.

• Liver function: assess baseline hepatic enzymes and monitor periodically.
• Cardiac status: evaluate for existing heart failure; avoid in decompensated cases.
• Drug interactions: review concomitant medications for CYP3A4 substrates.
• Pregnancy and lactation: use only if potential benefit outweighs risk.
• Renal impairment: adjust dosing in severe kidney disease.
• Store below 25°C: keep in the original pack, protect from moisture.

Itraconazole interacts with several drugs through metabolic pathways.

Major Interactions (Avoid)

• Rifampicin: induces CYP3A4, markedly reducing itraconazole levels.
• St. John’s wort: strong CYP3A4 inducer, may lead to therapeutic failure.
• Certain antiarrhythmics (e.g., amiodarone): increase risk of cardiac toxicity.

Moderate Interactions (Monitor Closely)

• Statins (e.g., simvastatin): may raise statin concentrations, monitor for myopathy.
• Benzodiazepines (e.g., midazolam): increased sedation, adjust dose if needed.
• Proton pump inhibitors: may reduce absorption, consider timing adjustments.